Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 By Ogkologos - July 1, 2025 604 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KOMET study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ΚΑΡΚΙΝΟΣ ΤΟΥ ΜΑΣΤΟΥ February 10, 2019 Activity and Safety of Regorafenib Plus Nivolumab in First-Line Treatment for... February 22, 2024 Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer January 24, 2022 Foodie Fridays-Gazpacho: A Favorite Summer Soup August 6, 2021 Load more HOT NEWS NCI-MATCH Update: More Labs, New Arms, and Initial Findings The Childhood Cancer Data Initiative: Transforming the Pediatric Cancer Landscape through... Scientists find cells in centre of tumours are most likely to... Vax-On Points to Maintenance of Active Anticancer Treatment Throughout the Whole...
